SG11201906132UA - Insoluble complex or solvate thereof, pharmaceutical composition and use thereof - Google Patents

Insoluble complex or solvate thereof, pharmaceutical composition and use thereof

Info

Publication number
SG11201906132UA
SG11201906132UA SG11201906132UA SG11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA SG 11201906132U A SG11201906132U A SG 11201906132UA
Authority
SG
Singapore
Prior art keywords
solvate
pharmaceutical composition
insoluble complex
insoluble
complex
Prior art date
Application number
Inventor
Shanchun Zhang
Yihua Wang
Jiashi Peng
Kaisheng Cheng
Xiao Wang
Shu Gao
Hongzhang Sun
Xiaorong Lu
Original Assignee
Fruithy Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fruithy Holdings Ltd filed Critical Fruithy Holdings Ltd
Publication of SG11201906132UA publication Critical patent/SG11201906132UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
SG11201906132U 2017-03-27 2018-03-26 Insoluble complex or solvate thereof, pharmaceutical composition and use thereof SG11201906132UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710188001 2017-03-27
PCT/CN2018/080424 WO2018177232A1 (en) 2017-03-27 2018-03-26 Poorly soluble complex or solvate thereof, pharmaceutical composition, and application thereof

Publications (1)

Publication Number Publication Date
SG11201906132UA true SG11201906132UA (en) 2019-10-30

Family

ID=63675241

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906132U SG11201906132UA (en) 2017-03-27 2018-03-26 Insoluble complex or solvate thereof, pharmaceutical composition and use thereof

Country Status (17)

Country Link
US (1) US11084790B2 (en)
EP (1) EP3486233B1 (en)
JP (1) JP6923122B2 (en)
KR (1) KR102248445B1 (en)
CN (1) CN109996787B (en)
AU (1) AU2018241564B2 (en)
CA (1) CA3049220C (en)
DK (1) DK3486233T3 (en)
EA (1) EA039449B1 (en)
ES (1) ES2866401T3 (en)
HU (1) HUE053472T2 (en)
PH (1) PH12019501560A1 (en)
PL (1) PL3486233T3 (en)
PT (1) PT3486233T (en)
SG (1) SG11201906132UA (en)
TW (1) TWI740045B (en)
WO (1) WO2018177232A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483372A (en) * 2018-05-14 2019-11-22 南京诺瑞特医药科技有限公司 The salt of Bupivacaine
CN111983052B (en) * 2020-07-24 2023-03-31 合肥诺明药物安全研究有限公司 Quantitative analysis method for blood concentration of HYR-PB21 effective ingredient
KR20230133595A (en) 2022-03-11 2023-09-19 한국한의약진흥원 Composition for maintaining stability of serotonin contained in Vespa Velutina venom

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099293A1 (en) * 2002-05-23 2003-12-04 Danmarks Farmaceutiske Universitet Pharmacologically active salts
CA2529503A1 (en) * 2003-06-20 2004-12-29 Royer Biomedical, Inc. Drug polymer complexes
DK1809329T3 (en) * 2004-09-17 2012-04-02 Durect Corp CONTINUOUS LOCAL ANAESTIC COMPOSITION CONTAINING SAIB
US8920843B2 (en) 2007-11-07 2014-12-30 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
CZ2009762A3 (en) 2009-11-16 2011-05-25 Zentiva, K. S. Novel salts of 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate known under unprotected name prasugrel and process of their preparation
CN104370934B (en) * 2013-08-13 2018-04-06 上海科胜药物研发有限公司 A kind of prasugrel salt and preparation method thereof
CN107848973A (en) * 2015-09-01 2018-03-27 四川海思科制药有限公司 The dimethylaniline formyl piperidine crystal of 1 propyl group of S () 2 ', 6 ' and its sustained release preparation
EP3558279A4 (en) 2016-12-26 2020-12-02 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain

Also Published As

Publication number Publication date
EA039449B1 (en) 2022-01-28
TWI740045B (en) 2021-09-21
CA3049220C (en) 2022-03-29
AU2018241564A1 (en) 2019-05-30
JP6923122B2 (en) 2021-08-18
KR102248445B1 (en) 2021-05-04
EP3486233A4 (en) 2020-04-08
TW201940170A (en) 2019-10-16
WO2018177232A1 (en) 2018-10-04
US20210087144A1 (en) 2021-03-25
PT3486233T (en) 2021-03-18
PL3486233T3 (en) 2021-06-28
HUE053472T2 (en) 2021-06-28
AU2018241564B2 (en) 2020-07-02
US11084790B2 (en) 2021-08-10
EA201990419A1 (en) 2019-09-30
KR20190101980A (en) 2019-09-02
JP2020515513A (en) 2020-05-28
ES2866401T3 (en) 2021-10-19
EP3486233B1 (en) 2021-01-27
CN109996787A (en) 2019-07-09
PH12019501560A1 (en) 2020-02-24
CA3049220A1 (en) 2018-10-04
CN109996787B (en) 2022-07-05
DK3486233T3 (en) 2021-03-15
EP3486233A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
IL269061A (en) Pharmaceutical composition comprising selexipag
EP3434285A4 (en) Pharmaceutical composition and use thereof
HK1256674A1 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
IL271226A (en) Pharmaceutical formulation
IL273339A (en) Griseofulvin compound and pharmaceutical use thereof
IL248785B (en) N-[1,5-dimethyl-3-oxo-(2,3-dihydro-1h-pyrazol-4-yl)]-4-methyl-isoxazole-3-carboxamide derivatives and pharmaceutical compositions comprising said derivatives
PT3606511T (en) Pharmaceutical composition comprising lenvatinib mesylate
IL248773B (en) 1,6-naphthyridine-4,5-dione derivatives and pharmaceutical compositions comprising them
SG11201906132UA (en) Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
EP3773654C0 (en) Polypharmaceutical drug compositions and related methods
HK1245113A1 (en) Pharmaceutical compositions and use thereof
FI3601277T3 (en) Pharmaceutical formulation
IL262929B1 (en) Composition, and application and pharmaceutical preparation thereof
IL275144A (en) Pharmaceutical formulation
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
EP3718543A4 (en) Pharmaceutical composition and use thereof
IL237283A0 (en) Dldh, derivatives thereof and formulations comprising same for use in medicine
HK1254527A1 (en) Pharmaceutical formulation and use thereof
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201812022D0 (en) Pharmaceutical methods and compositions
GB201719873D0 (en) Pharmaceutical formulation